Cynata Therapeutics (ASX:CYP) said it will act as a core partner in the Solutions for Manufacturing Advanced Regenerative Therapies Cooperative Research Center (SMART CRC), which recently received Australian Government funding, according to a Thursday filing with the Australian bourse.
SMART CRC is a AU$238 million national initiative with over 60 industry, government, healthcare, universities, and research institute partners, the filing said.
The partners will now move to draft and execute formal agreements, per the filing.
Shares were up 3% in afternoon trade on Thursday.
Price (AUD): $0.20, Change: $+0.0050, Percent Change: +2.63%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.